Renibus Therapeutics

Focus: Renibus Therapeutics is a small-molecule biotech focused on infectious diseases and nephrology, operating at pre-revenue stage with a lean team of 51-200 employees founded in 2023.

Infectious Diseases Nephrology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

About Renibus Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Renibus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG)

Post-discharge Outcomes

N/A

Clinical Trials (1)

NCT07009340Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery

N/A

Help build intelligence for Renibus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape drug development strategy across infectious diseases and nephrology with a Phase 3 asset (RBT-1) advancing toward potential near-term catalysts.
Small team structure (51-200 employees) enables broad cross-functional exposure and rapid skill development compared to large pharma.
Focused pipeline on high-unmet-need areas: post-operative cardiac complications, acute kidney injury, and COVID-19 represent addressable markets.

Watch Out For

Pre-revenue stage with no disclosed funding, cash position, or financial runway—significant sustainability and runway uncertainty for career stability.
Zero active job openings at time of analysis suggests hiring freeze or very limited growth phase, reducing near-term employment prospects.
Newly founded (2023) with no published research output (0 publications) and limited external validation of scientific approach or team track record.

Generated by Claude from Renibus Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RBT-1

Post-Operative Complications in Cardiac Surgery

N/A

Clinical Trials (1)

NCT06092970An Evaluation of Patient Reported Outcomes and Clinical Outcomes

N/A

FeS and SnPP

Acute Kidney Injury

PHASE_1

Clinical Trials (1)

NCT03630029RBT-1 Phase 1b Clinical Trial in Healthy Volunteers and Subjects With CKD

Phase 1